ReviewInfection & chemotherapy2015
Antiviral Treatment Guidelines for Middle East Respiratory Syndrome.
Review in Infection & chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis.Indian journal of medical microbiology · 2021Pooled it
- A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.Journal of medical virology · 2020Pooled it
- Risk Evaluation and Mitigation Strategies for Newly Detected Mysterious Dinga Dinga Virus Infection in Africa: A Narrative Review.Health science reports · 2025Article
- Evaluation of Laboratory Findings of Patients with Coronavirus Disease 2019 in Kerman, Iran.Iranian journal of pathology · 2023Article
- Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system.Microbial pathogenesis · 2022Review
- In silico identification of SARS-CoV-2 cell entry inhibitors from selected natural antivirals.Journal of molecular graphics & modelling · 2021Article
- Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.World journal of clinical cases · 2021Article
- Middle East Respiratory Syndrome (MERS) Virus-Pathophysiological Axis and the Current Treatment Strategies.AAPS PharmSciTech · 2021Review
- Discovery of anti-MERS-CoV small covalent inhibitors through pharmacophore modeling, covalent docking and molecular dynamics simulation.Journal of molecular liquids · 2021Article
- Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19.Journal of medical virology · 2021Article
- Insights on 3D Structures of Potential Drug-targeting Proteins of SARS-CoV-2: Application of Cavity Search and Molecular Docking.Molecular informatics · 2021Article
- Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection.Frontiers in pharmacology · 2021Review
- Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach.Qatar medical journal · 2021Article
- Aspects of Epidemiology, Pathology, Virology, Immunology, Transmission, Prevention, Prognosis, Diagnosis, and Treatment of COVID-19 Pandemic: A Narrative Review.International journal of preventive medicine · 2021Review
- A narrative review on the basic and clinical aspects of the novel SARS-CoV-2, the etiologic agent of COVID-19.Annals of translational medicine · 2020Review
- Pharmacological treatments of COVID-19.Pharmacological reports : PR · 2020Review
- Novel respiratory infectious diseases in Korea.Yeungnam University journal of medicine · 2020Article
- Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.Journal of clinical pharmacy and therapeutics · 2020Article
- Identification of potential inhibitors of SARS-CoV-2 main protease fromChemical physics letters · 2020Article
- Demographic, clinical, and outcomes of confirmed cases of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in Najran, Kingdom of Saudi Arabia (KSA); A retrospective record based study.Journal of infection and public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Middle East respiratory syndrome (MERS) is an acute infectious disease of the respiratory system caused by the new betacoronavirus (MERS coronavirus, MERS-CoV), which shows high mortality rates. The typical symptoms of MERS are fever, cough, and shortness of breath, and it is often accompanied by pneumonia. The MERS-CoV was introduced to Republic of Korea in May 2015 by a patient returning from Saudi Arabia. The disease spread mostly through hospital infections, and by the time the epidemic ended in August, the total number of confirmed diagnoses was 186, among which 36 patients died. Reflecting the latest evidence for antiviral drugs in the treatment of MERS-CoV infection and the experiences of treating MERS patients in Republic of Korea, these guidelines focus on antiviral drugs to achieve effective treatment of MERS-CoV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.